Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung.

2.50
Hdl Handle:
http://hdl.handle.net/10541/98094
Title:
Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung.
Authors:
Brewster, Alison E; Hopwood, Penelope; Stout, Ronald; Burt, Paul A; Thatcher, Nick
Abstract:
The effectiveness of a single 8-Gy fraction prophylactic cranial irradiation regime was assessed in 106 patients with small-cell carcinoma of the lung. All patients had limited stage disease and received combination chemotherapy consisting of either cisplatin or carboplatin with ifosfamide, etoposide, and vincristine (VICE). Cranial irradiation was administered 48 h after the first cycle of chemotherapy and was well tolerated. Actual 2-year survival was 35% and cranial relapse occurred in 22% of those patients who achieved complete remission. This compares favourably with a cranial relapse rate of 45% incomplete remitters previously reported with the same chemotherapy regime after a minimum follow-up of 2 years where PCI was not used. Formal psychometric testing was performed retrospectively on a series of 25 long-term survivors of whom 14 were taken from this reported series. Whilst 75% of patients were impaired on at least one test with 68% performing badly in the most complex task, this was not associated with clinically detectable neurological damage and the patients did not complain of memory or concentration difficulties. In conclusion, single fraction PCI, when used with platinum based combination chemotherapy, appears to be equally effective but may be less neurotoxic than the more standard fractionated regimes.
Affiliation:
Department of Radiotherapy, Christie Hospital, Manchester, UK.
Citation:
Single fraction prophylactic cranial irradiation for small cell carcinoma of the lung. 1995, 34 (2):132-6 Radiother Oncol
Journal:
Radiotherapy and Oncology
Issue Date:
Feb-1995
URI:
http://hdl.handle.net/10541/98094
DOI:
10.1016/0167-8140(95)01513-G
PubMed ID:
7597211
Type:
Article
Language:
en
ISSN:
0167-8140
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBrewster, Alison Een
dc.contributor.authorHopwood, Penelopeen
dc.contributor.authorStout, Ronalden
dc.contributor.authorBurt, Paul Aen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-05-06T16:03:14Z-
dc.date.available2010-05-06T16:03:14Z-
dc.date.issued1995-02-
dc.identifier.citationSingle fraction prophylactic cranial irradiation for small cell carcinoma of the lung. 1995, 34 (2):132-6 Radiother Oncolen
dc.identifier.issn0167-8140-
dc.identifier.pmid7597211-
dc.identifier.doi10.1016/0167-8140(95)01513-G-
dc.identifier.urihttp://hdl.handle.net/10541/98094-
dc.description.abstractThe effectiveness of a single 8-Gy fraction prophylactic cranial irradiation regime was assessed in 106 patients with small-cell carcinoma of the lung. All patients had limited stage disease and received combination chemotherapy consisting of either cisplatin or carboplatin with ifosfamide, etoposide, and vincristine (VICE). Cranial irradiation was administered 48 h after the first cycle of chemotherapy and was well tolerated. Actual 2-year survival was 35% and cranial relapse occurred in 22% of those patients who achieved complete remission. This compares favourably with a cranial relapse rate of 45% incomplete remitters previously reported with the same chemotherapy regime after a minimum follow-up of 2 years where PCI was not used. Formal psychometric testing was performed retrospectively on a series of 25 long-term survivors of whom 14 were taken from this reported series. Whilst 75% of patients were impaired on at least one test with 68% performing badly in the most complex task, this was not associated with clinically detectable neurological damage and the patients did not complain of memory or concentration difficulties. In conclusion, single fraction PCI, when used with platinum based combination chemotherapy, appears to be equally effective but may be less neurotoxic than the more standard fractionated regimes.en
dc.language.isoenen
dc.subjectBrain Canceren
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBrain Neoplasms-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshCisplatin-
dc.subject.meshCognition-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCranial Irradiation-
dc.subject.meshEtoposide-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMemory-
dc.subject.meshPsychomotor Performance-
dc.subject.meshRadiotherapy Dosage-
dc.subject.meshRemission Induction-
dc.subject.meshRetrospective Studies-
dc.subject.meshSurvival Rate-
dc.subject.meshVincristine-
dc.titleSingle fraction prophylactic cranial irradiation for small cell carcinoma of the lung.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy, Christie Hospital, Manchester, UK.en
dc.identifier.journalRadiotherapy and Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.